Skip to main content
Terug
BUHPF logo

Bumrungrad Hospital Public Company Limited

Datakwaliteit: 100%
Overbought
BUHPF
OTC Healthcare Medical - Care Facilities
€ 5,65
€ 0,00 (0,00%)
Marktkapitalisatie: 4,49B
Ook genoteerd als BUGDF OTC
Dagbereik
€ 5,65 € 5,65
52-Weeksbereik
€ 4,75 € 5,65
Volume
300
50D / 200D Gem.
€ 5,36 / € 4,98
Vorige Slotkoers
€ 5,65

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,6 0,3
P/B 0,2 2,9
ROE % 25,9 3,7
Net Margin % 29,9 3,8
Rev Growth 5Y % 19,2 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,00
€ 0,00 – € 0,00
 28 B 0
FY2026 € 0,00
€ 0,00 – € 0,00
 26 B 0

Belangrijkste Punten

Revenue grew 19,15% annually over 5 years — strong growth
ROE of 25,88% indicates high profitability
Net margin of 29,89% shows strong profitability
Debt/Equity of 0,02 — conservative balance sheet
Generating 6,59B in free cash flow
P/E of 0,60 — trading at a low valuation

Groei

Revenue Growth (5Y)
19,15%
Revenue (1Y)-2,35%
Earnings (1Y)-3,46%
FCF Growth (3Y)10,30%

Kwaliteit

Return on Equity
25,88%
ROIC21,22%
Net Margin29,89%
Op. Margin34,94%

Veiligheid

Debt / Equity
0,02
Current Ratio4,60
Interest Coverage1324,95

Waardering

P/E Ratio
0,60
P/B Ratio0,15
EV/EBITDA-0,30
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2,35% Revenue Growth (3Y) -0,52%
Earnings Growth (1Y) -3,46% Earnings Growth (3Y) 3,50%
Revenue Growth (5Y) 19,15% Earnings Growth (5Y) 57,63%
Profitability
Revenue (TTM) 25,11B Net Income (TTM) 7,51B
ROE 25,88% ROA 20,60%
Gross Margin 50,52% Operating Margin 34,94%
Net Margin 29,89% Free Cash Flow (TTM) 6,59B
ROIC 21,22% FCF Growth (3Y) 10,30%
Safety
Debt / Equity 0,02 Current Ratio 4,60
Interest Coverage 1324,95 Dividend Yield 0,03%
Valuation
P/E Ratio 0,60 P/B Ratio 0,15
P/S Ratio 0,18 PEG Ratio -5,76
EV/EBITDA -0,30 Dividend Yield 0,03%
Market Cap 4,49B Enterprise Value -2,61B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 25,11B 25,72B 25,38B 20,72B 12,46B
Net Income 7,51B 7,77B 7,01B 4,94B 1,22B
EPS (Diluted) 8,51 8,96 8,08 5,69 1,40
Gross Profit 12,69B 13,21B 12,48B 9,62B 4,73B
Operating Income 8,77B 9,17B 8,50B 6,01B 1,52B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 36,43B 32,65B 29,21B 24,26B 20,86B
Total Liabilities 5,60B 4,85B 5,11B 4,25B 3,24B
Shareholders' Equity 30,52B 27,49B 23,80B 19,71B 17,29B
Total Debt 487,29M 139,44M 91,14M 63,28M 94,37M
Cash & Equivalents 7,59B 3,26B 3,77B 2,09B 1,80B
Current Assets 18,77B 16,73B 15,68B 11,42B 8,06B
Current Liabilities 4,08B 3,83B 4,18B 3,41B 2,28B

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#360 of 827
46
Custom Contrarian Investing (David Dreman)
#439 of 670
19
Value Defensive Investing (Benjamin Graham)
#514 of 709
17
Value Value Investing (Warren Buffett)
#120 of 203
39

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026